Tirzepatide is a peptide that works on the GIP and GLP-1 receptors at the same time (formula C225H348N48O68, average mass 4,813 g/mol, CAS 2023788-19-2). Tirzepatide is sold here for laboratory research in 8 sizes (5mg to 60mg), from $50.00 a vial. It is not an FDA-approved medicine. Research use only, and never for people or animals.
Tirzepatide specifications
| Product name | Tirzepatide |
|---|---|
| Also sold as | Tirzepatide peptide, GLP-1/GIP dual agonist, tirz, tirzepatide research peptide |
| Formula | C225H348N48O68 |
| Average mass | 4,813 g/mol |
| CAS number | 2023788-19-2 |
| Physical form | Freeze-dried powder, a solid cake in a sealed vial |
| Appearance | White to off-white cake |
| Sizes on this page | 5mg · 10mg · 15mg · 20mg · 30mg · 40mg · 50mg · 60mg |
| Purity specification | ≥99% by RP-HPLC. The number for the lot you receive is whatever its own certificate says. |
| Identity check | Mass spectrometry, read against the mass this compound should have |
| Net content | Weighed per lot and reported separately from purity |
| Lot documentation | 7 of 8 sizes have a published Kovera Labs certificate (10mg, lot LF-29B-2609; 15mg, lot LF-29C-2609; 20mg, lot LF-29D-2609; 30mg, lot LF-29E-2609; 40mg, lot LF-29F-2609; 50mg, lot LF-29G-2609; 60mg, lot LF-29H-2609); the other 1 is in testing |
| Storage | Sealed, cold and out of the light |
| Ships from | Santa Ana, California by USPS with tracking on every order, same business day on verified in-stock orders placed before 12 PM Pacific |
| Intended use | Laboratory research only. Not for human or animal use. |
What is Tirzepatide, and what is it used for?
Tirzepatide is a man-made peptide that works on two receptors at once, GIP and GLP-1. There are approved prescription medicines with this same active ingredient, and those come from a pharmacy against a prescription. What is sold here is laboratory material. It is not a medicine, not a stand-in for one, and not for human or animal use.
Tirzepatide is also listed and searched as Tirzepatide peptide, GLP-1/GIP dual agonist, tirz, tirzepatide research peptide, peptide tirzepatide. They all mean the same compound. Supplier lists write it as Tirzepatide peptides or peptide Tirzepatide as well; every one of those is this record.
Because a prescription medicine shares this ingredient, a wrong label here causes more trouble than usual. So the record below shows what was actually tested, not what a supplier said.
Chemically: molecular formula C225H348N48O68, average mass 4813 g/mol (PubChem CID 166567236). Those figures are what the identity test on a certificate is read against.
Frequently mistyped as tirzepitide, terzepatide, tirzeptide. Those spellings reach this same record.
A peptide that works on the GIP and GLP-1 receptors at the same time.
It switches on both the GIP receptor and the GLP-1 receptor. Working on two rather than one is the design feature that separates it from the GLP-1-only drugs.
There is a large published clinical record: how it behaves at the receptors, how the body handles it, and the measurements its sponsor registered its trials to take. Approved medicines containing it exist under their own brand names.
What is sold here is a research chemical, not a drug product. Listing it is not an approval, and not a claim that it is equivalent to, as safe as, or a fit substitute for any approved medicine.
Tirzepatide for sale: 5mg to 60mg (8 sizes) vials, price per mg
Tirzepatide is sold in 8 sizes here, 5mg to 60mg (8 sizes), from $50.00 a vial. Tirzepatide cost and Tirzepatide price per mg by size are in the table, at each volume tier and on subscription; the per-mg figure under each price is the one that compares across sizes.
Volume and subscription pricing by size
| Size | One vial | 10–19 vials−10% | 20 vials−15% | Subscribe monthly−6% from shipment 2 | Availability |
|---|---|---|---|---|---|
| Tirzepatide 5mg | $50.00$10.00/mg | $45.00a vial · $9.00/mg | $42.50a vial · $8.50/mg | $47.00a vial, shipment 2 on · $9.40/mg | Backordered — waitlist |
| Tirzepatide 10mg | $90.00$9.00/mg | $81.00a vial · $8.10/mg | $76.50a vial · $7.65/mg | $84.60a vial, shipment 2 on · $8.46/mg | In stock |
| Tirzepatide 15mg | $95.00$6.33/mg | $85.50a vial · $5.70/mg | $80.75a vial · $5.38/mg | $89.30a vial, shipment 2 on · $5.95/mg | In stock |
| Tirzepatide 20mg | $125.00$6.25/mg | $112.50a vial · $5.63/mg | $106.25a vial · $5.31/mg | $117.50a vial, shipment 2 on · $5.88/mg | In stock |
| Tirzepatide 30mg | $150.00$5.00/mg | $135.00a vial · $4.50/mg | $127.50a vial · $4.25/mg | $141.00a vial, shipment 2 on · $4.70/mg | In stock |
| Tirzepatide 40mg | $155.00$3.88/mg | $139.50a vial · $3.49/mg | $131.75a vial · $3.29/mg | $145.70a vial, shipment 2 on · $3.64/mg | In stock |
| Tirzepatide 50mg | $225.00$4.50/mg | $202.50a vial · $4.05/mg | $191.25a vial · $3.83/mg | $211.50a vial, shipment 2 on · $4.23/mg | In stock |
| Tirzepatide 60mgBest per mg | $230.00$3.83/mg | $207.00a vial · $3.45/mg | $195.50a vial · $3.26/mg | $216.20a vial, shipment 2 on · $3.60/mg | In stock |
The 60mg vial works out 57% cheaper per mg than the 10mg. Volume tiers are per size and do not combine across sizes (see bulk pricing). Subscribe & Save takes 6% every month, 4% every 2 months or 2% every 3 months off from shipment 2, two shipments minimum, and stacks on the volume tier: the lowest this record ever bills is $3.06 per mg, twenty 60mg vials on a monthly subscription from shipment 2 onward.
Nothing is added at checkout except the USPS shipping you choose; dispatch and delivery are the same on every order. The cost-per-milligram tool ranks the whole catalog by price per mg. The certificate walked through field by field: Where to Buy Tirzepatide Peptide: Buyer Checks.
Where to buy Tirzepatide: what to check before you order from anyone
Where to get Tirzepatide, and how to buy Tirzepatide online
Tirzepatide for sale, or Tirzepatide peptide for sale, means this page: one record, 8 sizes. You can buy Tirzepatide online here with guest checkout, and purchase Tirzepatide or order Tirzepatide in any size below; verified in-stock orders placed before 12 PM Pacific are dispatched the same day. If the question is where to get Tirzepatide or how to get Tirzepatide, the answer for a US laboratory is a supplier who publishes the certificate before you pay, which is the first of the five checks that follow.
Before ordering Tirzepatide from anyone, us included, run the 5 checks on verifying a certificate; the first is that the report resolves on the laboratory's own site, and a seller who cannot pass them is asking for the trust a certificate exists to replace.
Tirzepatide reviews
No customer review of Tirzepatide has been published yet, so there is no star rating here; when real ones exist the number will be the arithmetic of what people wrote. Ordered this record? Leave a review. A person reads every one before it appears.
Tirzepatide capsules, oral form or sublingual? What this vial is, and is not
Search results for Tirzepatide also show capsules, oral form, sublingual products, under listing titles such as tirzepatide pills, tirzepatide tablets, tirzepatide pill, tirzepatide pill form, tirzepatide tablet, tirzepatide vial. Those are finished consumer goods made and marketed by other companies, and none of them is what this page sells. This record is freeze-dried Tirzepatide in a sealed glass vial, 5mg to 60mg (8 sizes), with a lot certificate, supplied for laboratory work. Its certificate describes that powder, not a capsule, spray or cream, which carry other ingredients and sit under different rules.
Tirzepatide vs Semaglutide: different molecules, separate records
Tirzepatide vs Semaglutide, or Semaglutide vs Tirzepatide, is the comparison people search most, and they are not the same thing. Each is a different molecule with a different formula, mass and research record, and each has its own certificate here.
Semaglutide vs Tirzepatide: the same comparison, side by side
| Record | Class | Formula | Avg. mass | Sizes here |
|---|---|---|---|---|
| Tirzepatide | A peptide that works on the GIP and GLP-1 receptors at the same time. | C225H348N48O68 | 4813 | 5mg · 10mg · 15mg · 20mg · 30mg · 40mg · 50mg · 60mg · 70mg · 80mg · 90mg · 100mg · 110mg · 120mg from $50.00 |
| Semaglutide | A peptide that works on the GLP-1 receptor. | C187H291N45O59 | 4114 | 5mg · 10mg · 15mg · 20mg · 30mg from $55.00 |
Documentation compared in full: Tirzepatide vs Semaglutide, side by side.
Tirzepatide guides and documentation
Written to answer the questions that come up around Tirzepatide specifically, what its paperwork should show, how it is handled, and how to judge a supplier selling it.
- Which peptides are FDA approved: eleven drug substances and their records
- Is Tirzepatide a peptide? Yes, a 39-residue chain with a fatty diacid attached
- Popular peptides, sorted by what the literature actually studies
- Tirzepatide certificates of analysis, field by field, and how to verify the lot
- Tirzepatide identity testing: confirming the dual-agonist sequence by mass
- Tirzepatide storage and stability: what the record actually supports
The full library, grouped by what you came to answer, is in the laboratory guides.
The Tirzepatide certificate: lot, purity, identity, and how to verify it
A certificate answers identity, purity and net content as three separate questions, each with the method that produced it and the date it was run, how to read one covers what each field does and does not cover. For Tirzepatide that means a mass spectrum landing on 4,813 g/mol for C225H348N48O68, the figure published against PubChem CID 166567236. The cataloged form is Tirzepatide, and the identity test resolves to that rather than to a related molecule with a similar name.
| Size | Lot | Identity method | Purity | Endotoxin · sterility · fentanyl | Test date |
|---|---|---|---|---|---|
| 10mg | LF-29B-2609 | LC-MS | 99.449% (RP-HPLC, C18, DAD @ 214 nm) | Pass · pass · not detected | 2026-10-07 |
| 15mg | LF-29C-2609 | LC-MS | 99.784% (RP-HPLC, C18, DAD @ 214 nm) | Pass · pass · not detected | 2026-10-07 |
| 20mg | LF-29D-2609 | LC-MS | 99.696% (RP-HPLC, C18, DAD @ 214 nm) | Pass · pass · not detected | 2026-10-07 |
| 30mg | LF-29E-2609 | LC-MS | 99.761% (RP-HPLC, C18, DAD @ 214 nm) | 2026-09-29 | |
| 40mg | LF-29F-2609 | LC-MS | 99.859% (RP-HPLC, C18, DAD @ 214 nm) | Pass · pass · not detected | 2026-10-07 |
| 50mg | LF-29G-2609 | LC-MS | 99.526% (RP-HPLC, C18, DAD @ 214 nm) | Pass · pass · not detected | 2026-10-07 |
| 60mg | LF-29H-2609 | LC-MS | 99.746% (RP-HPLC, C18, DAD @ 214 nm) | Pass · pass · not detected | 2026-10-07 |
Testing by Kovera Labs. Every batch tested on or after October 1, 2026 includes endotoxin, sterility and fentanyl screening, in addition to identity, purity and net content. Open the report, then confirm it on the issuing laboratory's own site. If the identifier does not resolve there, or resolves to a different lot than the one printed on your vial, the document is worthless however convincing it looks.
- Certificate for lot LF-29B-2609 · Report PDF · Endotoxin report · Sterility report · Verify at Kovera Labs
- Certificate for lot LF-29C-2609 · Report PDF · Endotoxin report · Sterility report · Verify at Kovera Labs
- Certificate for lot LF-29D-2609 · Report PDF · Endotoxin report · Sterility report · Verify at Kovera Labs
- Certificate for lot LF-29E-2609 · Report PDF · Verify at Kovera Labs
- Certificate for lot LF-29F-2609 · Report PDF · Endotoxin report · Sterility report · Verify at Kovera Labs
- Certificate for lot LF-29G-2609 · Report PDF · Endotoxin report · Sterility report · Verify at Kovera Labs
- Certificate for lot LF-29H-2609 · Report PDF · Endotoxin report · Sterility report · Verify at Kovera Labs
The lot number on the certificate must match the lot printed on the vial you received. That match is the only thing tying the document to your material. Net content is reported separately from purity, because a vial can be highly pure and still hold less material than its label states.
Is Tirzepatide legal? FDA status, and what this listing is
FDA status, and what this listing is Approved as a prescription medicine, compounding discretion ended 2025
The FDA declared the tirzepatide injection shortage over on 19 December 2024. When a shortage ends, the temporary permission pharmacies had to compound the drug ends with it: that ran out on 19 February 2025 for 503A compounding pharmacies and 19 March 2025 for 503B outsourcing facilities. So compounded tirzepatide is no longer generally allowed. Research-grade material was never a lawful route to human use at any point in that story.
Status verified 2026-08-25. Check the primary source before relying on this summary.
Whether Tirzepatide is legal depends on what it is being used for and where. It is sold as laboratory material under the research-use restriction below. Being listed is not an approval, and not a claim that it is safe, effective or right for any purpose. LabFirst is not a pharmacy or a compounding facility, this vial is not a compounded medicine, and no prescription is involved, because it is not sold for use in anyone. Search results also show compound Tirzepatide and Tirzepatide compound offers from compounding pharmacies; a compounded Tirzepatide is a prescription product prepared for a named patient, and a certificate for this lot says nothing about one. Sports bodies keep their own prohibited lists; whether a substance is banned in competition is a question for the relevant anti-doping authority, not for a supplier.
Sources checked 2026-08-25: NCPA, FDA ends compounding discretion for tirzepatide · Alston & Bird, FDA resolves the shortage: next steps
Tirzepatide research: what the published studies examine
Status: Approved medicines exist, this material is not one of them. Tirzepatide works on two receptors at once, GIP and GLP-1. FDA-approved medicines containing it exist, they are prescription only, and they are made under pharmaceutical quality rules that a research-chemical supply chain does not copy.
Tirzepatide, developed as LY3298176, is a peptide with a fatty acid attached that switches on both the GIP receptor and the GLP-1 receptor. Two things about it are more specific than "dual agonist" suggests. It does not treat the two equally: across the range studied it sits on the GIP receptor more than on the GLP-1 receptor.
And at the GLP-1 receptor it does not simply act weaker, it acts differently, favoring one signalling route (cAMP) over another (beta-arrestin) and pulling the receptor inside the cell less than the body’s own GLP-1 does. That matters because beta-arrestin1 appears to hold back the insulin response to GLP-1 but not to GIP or to tirzepatide, so the lopsided signalling is offered as part of how the molecule works rather than a footnote. At the GIP receptor it behaves much like the body’s own GIP.
The fatty acid lets it ride on albumin in the blood, which is how it stays in circulation for so long, the same trick used across this class.
| Reported observation | Model | Source |
|---|---|---|
| In cell tests the compound switched on both GIP and GLP-1 receptor signalling, and in mice it raised insulin release in a glucose-dependent way through both receptors. Given to mice over a longer period, it cut body weight and food intake by more than a GLP-1-only comparator did, which is the exact comparison the two-receptor design was built to test. | cell lines expressing recombinant and endogenous incretin receptors, and mice | Coskun and colleagues, LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept, Molecular Metabolism (2018)Sponsor-authored. The paper also carries a phase 1 human component that is not summarized here. |
| Modeling of how much of the compound sits on each receptor showed more on GIP than on GLP-1, supporting the lopsided picture. Signalling tests found it copies the body’s own GIP at the GIP receptor but behaves differently at the GLP-1 receptor, favoring cAMP over beta-arrestin and pulling the receptor inside the cell less than GLP-1 does. In islet cells from mice, beta-arrestin1 held back the insulin response to GLP-1 but not to GIP or to tirzepatide. | receptor occupancy modeling, signalling assays, primary mouse islets and knockout mice | Willard and colleagues, Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist, JCI Insight (2020)Co-authored with academic groups at Duke and the University of Copenhagen, so this signalling work is not wholly sponsor-internal. |
Open questions. How this compound behaves at its receptors is unusually well described for a peptide sold in this market. The lopsided-signalling account is best read as a good theory about why two receptors beat one, not as settled fact. Clinical results are left out on purpose, for the same reason given on the retatrutide page. And there is a naming problem worth saying plainly: because an approved medicine carries this name, a research vial labeled tirzepatide gets assumed to be the same thing, and it has not earned that.
Whether a given vial holds the right sequence is a question about that lot, answered by an identity test and not by the word on a label.
Each row above describes an observation in the stated model. None of it describes what Tirzepatide would do in a person or an animal outside that model, and none of it is a recommendation to use it for anything.
How to store Tirzepatide: refrigeration and shelf life
Keep the sealed vial cold and out of the light and it stays as it left the lab. Once it is mixed into a solution, how long it holds up depends on the compound, what it was mixed with, how strong the solution is and how cold it is kept — too many variables for anyone to print one shelf life on a label. So laboratories write the date on whatever they prepare and keep their own record of it.
For solution preparation arithmetic on the bench, concentration, per-graduation values and molarity, use the vial concentration calculator, which opens with the Tirzepatide sizes stocked here already loaded. It covers laboratory measurement only and contains no administration guidance.
